Research · Sep 3, 2026
[MEDP] Medpace Holdings Thesis 2026: Mid-Cap Biotech CRO Cycle Drives Backlog Conversion Recovery
Medpace Holdings Inc. (NASDAQ: MEDP) FY2025 revenue ~$2.3-2.5B (+8-15%) with adj. EPS ~$13.50-15.00 reflecting continued post-2024 ~$3.0-3.3B aggregate backlog (~+5-10% YoY) + selected continued post-2024 selected primary mid-cap biotech + selected various small-cap biotech CRO market leadership + selected continued post-2024 selected various Phase II + Phase III + selected various therapeutic-focused clinical trial services under continued President + CEO August Troendle since 1992 (~33-year tenure as Medpace Founder + CEO; selected ~25%+ Troendle family + Founder family aggregate ownership). One of the largest US mid-cap + small-cap biotech-focused Contract Research Organizations (CRO). Founded 1992 as Medpace by August Troendle (~33-year heritage); selected post-2014 ~$915M aggregate Cinven (UK-based private equity) acquisition; selected post-August 2016 NASDAQ listing IPO via secondary offering (~$255M aggregate raised). Headquartered in Cincinnati Ohio; ~6,000+ employees globally with ~$2.3-2.5B revenue. One primary segment: Clinical Trial Services + Selected Various (~100% ~$2.3-2.5B). End market mix: Mid-cap + small-cap biotech ~80%+ + Large-cap pharma ~10% + Government ~5-10%. Therapeutic mix: Oncology ~30%+ + Cardiology + Metabolic ~20% + Neurology + CNS ~15-20% + Antiviral + Infectious Disease ~10% + selected various ~25-30%. Mid-cap biotech CRO cycle: ~$3.0-3.3B aggregate backlog; selected primary mid-cap biotech + small-cap biotech CRO market leadership; biotech funding + clinical trial demand recovery. Therapeutic-focused clinical trial services: oncology + cardiology + neurology + therapeutic-focused capability. President + CEO August Troendle since 1992 (~33-year tenure); CFO Kevin Brady. Capital + cash position: ~$300-450M aggregate cash + investments balance; ~$0M aggregate net debt position; modest opportunistic buybacks; ~$300-500M aggregate FY2024-2025 buyback program (~$150-300M aggregate FY2025); aggregate capital return ~$150-300M; selected ~25%+ Troendle family + Founder family aggregate ownership; investment-grade pathway pre-credit-rating. FY2026 thesis: Mid-cap biotech CRO cycle + Therapeutic-focused clinical trial services + selected continued post-2024 selected various biotech funding + clinical trial demand recovery + ~$300-500M aggregate cash + investments balance + ~$0M aggregate net debt + ~$150-400M aggregate annual buybacks + selected continued ~25%+ Troendle family + Founder family aggregate ownership + selected potential post-2024 dividend initiation. Risks: mid-cap biotech CRO cyclical, IQVIA + ICON + Charles River competition, biotech funding cycle, clinical trial cancellation, ~25%+ Troendle family ownership concentration.